Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial

American Heart Journal

Volumn 152, Issue 3, 2006, Pages 448.e1-448.e7

  Bostom, Andrew G ^a   Carpenter, Myra A ^b   Kusek, John W ^c   Hunsicker, Lawrence G ^d   Pfeffer, Marc A ^e   Levey, Andrew S ^f   Jacques, Paul F ^g   McKenney, Joyce ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b IL   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT RECIPIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33747204679     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.03.004     Document Type: Article

References (35)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 5 Suppl 3 (1998) S112-S119
2. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
3. Shlipak M.G., Fried L.F., Cushman M., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
4. Bostom A.G., and Culleton B.F. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10 (1999) 891-900
5. Linnell J.C., and Bhatt H.R. Inherited errors of cobalamin metabolism and their management. Baillieres Clin Haematol 8 (1995) 567-601
6. Mudd S.H., Levy H.L., and Skovby F. Disorders of transsulfuration. In: Scriver C.R., and Beaudet A.L. (Eds). Metabolic basis of inherited disease. 6th ed (1989), McGraw Hill, Inc, New York
7. Rosenblatt D.S. Inherited disorders of folate transport and metabolism. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). Metabolic basis of inherited disease. 6th ed. (1989), McGraw Hill, Inc., New York 2049-2064
8. Mudd S.H., Skovby F., Levy H.L., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37 (1985) 1-31
9. Wilcken D.E., and Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20 (1997) 295-300
10. Ueland P.M., Refsum H., Stabler S.P., et al. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39 (1993) 1764-1779
11. Ueland P.M., Refsum H., Beresford S.A., et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72 (2000) 324-332
12. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 5 (2005) 215-222
13. Jacques P.F., Selhub J., Bostom A.G., et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340 (1999) 1449-1454
14. Massy Z.A., Chadefaux-Vekemans B., Chevalier A., et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9 (1994) 1103-1108
15. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17 (1997) 2554-2558
16. Ducloux D., Motte G., Challier B., et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11 (2000) 134-137
17. Jungers P., Chauveau P., Bandin O., et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 23 (1997) 170-173
18. Moustapha A., Naso A., Nahlawi M., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97 (1998) 138-141
19. Winkelmayer W.C., Kramar R., Curhan G.C., et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 16 (2005) 255-260
20. Bostom A.G., Gohh R.Y., Liaugaudas G., et al. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis 145 (1999) 221-224
21. Beaulieu A.J., Gohh R.Y., Han H., et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol 19 (1999) 2918-2921
22. Bostom A.G., Gohh R.Y., Beaulieu A.J., et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 127 (1997) 1089-1092
23. Bostom A.G., Shemin D., Gohh R.Y., et al. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 69 (2000) 2128-2131
24. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
25. Piantadosi S. Clinical trials: a methodologic perspective (1997), Wiley, New York
26. Herzog C. The USRDS and its products. United States Renal Data System. Am J Kidney Dis 30 2 Suppl 1 (1997) S21-S39
27. Elashoff JD, nQuery Advisor Version 4.0 User's Guide 2000. Los Angeles: Karger Publishers
28. Lan K.K.G., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663
29. Halperin M., Lan K.K., Ware J.H., et al. An aid to data monitoring in long-term clinical trials. Control Clin Trials 3 (1982) 311-323
30. SAS Institute. SAS language reference: concepts, version 8 (1999), SAS Institute Inc., Cary (NC)
31. Baker F., Picton D., Blackwood S., et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation 106 (2002) II-741
32. Bonaa K.H. NORVIT: randomised trial of homocysteine-lowering with B-vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. European Society of Cardiology Congress. Stockholm, Sweden (2005)
33. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
34. Wrone E.M., Hornberger J.M., Zehnder J.L., et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 (2004) 420-426
35. Bostom A.G., Shemin D., Gohh R.Y., et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int Suppl 78 (2001) S246-S252